More Space More Dose: Dose Report of the First Patients With Intermediate- and High-Risk Prostate Cancer Treated in Cologne With Hydrogel Before HDR-brachytherapy Boost and External Beam IMRT

Abstract

Conclusions: Hypofractionated VMAT-IGRT in prostate cancer patients is dosimetrically and clinically feasible. Acute toxicity and impairment of QLQ were acceptable and similar to other hypofractionated series. Further following is required to assess late toxicity and disease control. Author Disclosure: J. Salinas: None. A. Serna: None. A. Iglesias: None. F. Mata: None. P.P. Escolar: None. V. Puchades: None. M.A. Gomez: None. D. Ramos: None.